Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined With Pegylated Interferon in Subjects With Chronic Hepatitis B
NCT04426968 is registered in ClinicalTrials.gov with Shanghai HEP Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined With Pegylated Interferon in Subjects With Chronic Hepatitis B
- Lead sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 18, 2021
- Completion date
- November 29, 2023
- Enrollment
- 96 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.